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Abstract
Background: Cyclophilin A (CypA) represents a potential key molecule in future antiretroviral therapy since
inhibition of CypA suppresses human immunodeficiency virus type 1 (HIV-1) replication. CypA interacts with the
virus proteins Capsid (CA) and Vpr, however, the mechanism through which CypA influences HIV-1 infectivity still
remains unclear.
Results: Here the interaction of full-length HIV-1 Vpr with the host cellular factor CypA has been characterized and
quantified by surface plasmon resonance spectroscopy. A C-terminal region of Vpr, comprising the 16 residues
75GCRHSRIGVTRQRRAR
90, with high binding affinity for CypA has been identified. This region of Vpr does not
contain any proline residues but binds much more strongly to CypA than the previously characterized N-terminal
binding domain of Vpr, and is thus the first protein binding domain to CypA described involving no proline
residues. The fact that the mutant peptide Vpr
75-90 R80A binds more weakly to CypA than the wild-type peptide
confirms that Arg-80 is a key residue in the C-terminal binding domain. The N- and C-terminal binding regions of
full-length Vpr bind cooperatively to CypA and have allowed a model of the complex to be created. The
dissociation constant of full-length Vpr to CypA was determined to be approximately 320 nM, indicating that the
binding may be stronger than that of the well characterized interaction of HIV-1 CA with CypA.
Conclusions: For the first time the interaction of full-length Vpr and CypA has been characterized and quantified.
A non-proline-containing 16-residue region of C-terminal Vpr which binds specifically to CypA with similar high
affinity as full-length Vpr has been identified. The fact that this is the first non-proline containing binding motif of
any protein found to bind to CypA, changes the view on how CypA is able to interact with other proteins. It is
interesting to note that several previously reported key functions of HIV-1 Vpr are associated with the identified N-
and C-terminal binding domains of the protein to CypA.
Background
The viral protein R (Vpr) is encoded by the human
immunodeficiency viruses types 1 and 2 (HIV-1/HIV-2),
the simian immunodeficiency viruses (SIV) and primate
lentiviruses [1,2]. This accessory protein facilitates trans-
port of the pre-integration complex into the nucleus of
non-dividing cells [3] and fulfils multiple functions in
the viral life cycle, including increase of viral replication
in non-dividing host cells, induction of G2 cell-cycle
arrest [4,5], apoptosis [6,7] and transduction through
cell membranes [8] (The multiple functions of Vpr are
reviewed in [9-11]). Vpr interacts with several cellular
factors, including the human peptidyl prolyl isomerase
cyclophilin A (CypA) [12-14]. One of the main problems
with existing antiretroviral therapy is that the viruses
can develop drug resistance, which necessitates identifi-
cation of new potential drug targets that overcome this
problem. One approach that recently has received
increased attention, is targeting host factors essential for
t h ep a t h o g e nl i f ec y c l e ,r a t h e rt h a np a t h o g e nc o m p o -
nents directly [15-17]. CypA could be such a target as it
is dispensable for cell viability [18,19], and viral
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inhibited by use of selective inhibitors of CypA [20-25].
Recently, we investigated the interactions of CypA
with the N-terminus of Vpr at atomic resolution [14].
Prolyl cis/trans isomerization of the highly conserved
proline residues Pro-5, -10, -14 and -35 of Vpr are cata-
lyzed by human CypA and require only very low con-
centrations of the isomerase relative to that of the
peptide substrates. However, of the N-terminal peptides
of Vpr investigated, only those containing Pro-35, which
appears to be vital for manifold functions of Vpr, bind
to CypA in surface plasmon resonance (SPR) biosensor
experiments. Extensive analysis revealed that the binding
region of N-terminal Vpr to CypA consisted of the hep-
tapeptide motif RHFPRIW centered at Pro-35 [14].
The biological significance of the interaction of Vpr
with CypA, including the extensively studied interaction
of CypA with HIV-1 capsid (CA), that is crucial for viral
replication [26,27], is still not completely understood
(Reviewed in [25,28]). However, specific inhibitors of the
prolyl cis/trans isomerase activity of CypA, such as
cyclosporine A and SDZ-NIM811, inhibit HIV-1 replica-
tion [20-25] and a possible role of CypA in both entry
and postentry events of the viral life cycle of HIV-1 has
been indicated [29]. The interaction of HIV-1 Vpr with
CypA is known to occur in vitro and in vivo [12,13,25],
although the biological consequences thereof are dis-
puted. The original reports concluded that CypA had
significance for the de novo synthesis of Vpr, as the
Vpr-mediated cell cycle arrest in HIV-1 infected T cells
appeared to be eliminated in the absence of CypA activ-
ity [13]. More recently it has been suggested that the
interaction of Vpr with CypA is independent of the abil-
ity of Vpr to induce G2 cell cycle arrest [12].
Independent of these data, previous studies have
unambiguously shown the N-terminal residues from
Ala-30 to Phe-34, which are adjacent to or incorporated
in the N-terminal binding region of Vpr to CypA, com-
prised of
32RHFPRIW
38 centered at Pro-35, are crucial
for the ability of Vpr to induce G2 cell cycle arrest
[30-32]. Similarly, the ability of Vpr to induce G2 cell
cycle arrest is also influenced by residues in the C-term-
inal region 71-90 [30,31,33-37].
All studies are in agreement that mutation of Pro-35
with Ala disrupts the interaction of Vpr with CypA
[12,13], which is consistent with a conformational
change in the hydrophobic core [38]. On the other
hand, intriguingly, Ardon et al. reported that mutation
of the C-terminal residue Arg-80 with Ala also pre-
vented coimmunoprecipitation of Vpr with CypA [12].
However, the molecular explanation for the latter C-
terminal mutation of Vpr to interfere with the interac-
tion of the protein with CypA has remained elusive [12].
Mutation of Arg-80 with Ala may cause a change in the
folded structure of full-length Vpr or, could in theory,
alter the structure of a specific novel C-terminal binding
region of Vpr to CypA. The Pro residues of HIV-1NL4-3
Vpr are located in the N-terminal domain of the pro-
tein, namely at positions 5, 10, 14 and 35. All previously
determined binding domains of various proteins inter-
acting with CypA have hitherto required at least one
Pro residue as part of the binding region.
However, a limited number of studies have shown that
CypA is able to bind to peptides that do not contain Pro
residues through an alternative non-Pro-dependent bind-
ing region [39]. According to Demange et al., CypA exhi-
bits two binding sites, of which the S1’ site requires a
Pro-containing substrate whereas the S2’-S3’ site facili-
tates binding to peptides that do not contain Pro [39].
Saphire et al. reported that a Vpr-CypA fusion protein
which has no isomerase activity and no capacity to bind
to CA also rescues HIV-1 replication, which may indicate
an important role of CypA associated with Vpr [40].
These facts, together with the observation of consider-
able amounts of CypA in virions [41] prompted us to
study the interaction of Vpr with CypA in order to iden-
tify potential novel binding sites. This paper presents
SPR binding studies of the interactions of CypA with
full-length synthetic Vpr (sVpr) and C-terminal sVpr
peptides. A novel specific non-Pro-containing C-term-
inal binding region of Vpr facilitating strong binding to
CypA has been identified. The contribution of this novel
C-terminal binding region together with the previously
characterized N-terminal binding region RHFPRIW cen-
tered at Pro-35 has been demonstrated through charac-
terization and quantification of the interaction of full-
length Vpr with CypA.
Results
To investigate the interaction between full-length Vpr
and CypA in more detail, and to find an explanation for
the previously undefined role of the C-terminus of Vpr
with respect to this interaction, we performed interac-
tions studies by SPR spectroscopy between highly pure
recombinant CypA and full-length Vpr and C-terminal
Vpr peptides. Additionally, possibly structural changes
in the C-terminal region caused by substitution of Arg-
80 by Ala were investigated by nuclear magnetic reso-
nance (NMR) spectroscopy.
Characterization of the interaction of C-terminal Vpr
75-90
with CypA using surface plasmon resonance spectroscopy
SPR data obtained for the interaction of C-terminal
Vpr
75-90 with immobilized CypA revealed that the pep-
tide binds strongly to CypA (Figure 1A, B). A compari-
son of sensorgrams obtained for the interactions of
immobilized CypA with C-terminal Vpr
75-90 and the N-
terminal peptide Vpr
30-40 containing the N-terminal
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Page 2 of 16binding region of Vpr to CypA [14], respectively, using
the same analyte concentration (1-8 μM )a n dc h i pd e n -
sity of immobilized CypA (180 response units (RU))
(Figure 1B, C), showed that Vpr
75-90 has strongest bind-
ing to CypA. The magnitude of the SPR response is due
to changes in the refractive index caused by mass
changes, brought about by binding of analyte to ligand
at the chip surface [42-44]. The SPR-angle response is
converted to RU (1 RU = 0.0001°), which is equivalent
to 1 pg/mm
2 of bound protein [44]. As Vpr
30-40 has a
slightly lower molecular weight than Vpr
75-90, a poten-
tial binding response would therefore be expected to be
somewhat lower than for Vpr
75-90,p r o v i d e dt h a tt h e
binding regions of the peptides have equal affinity for
immobilized CypA. Nonetheless, the large difference in
response observed for Vpr
75-90 compared with Vpr
30-40
(Figure 1B, C) can not be explained by the difference in
molecular weight between the peptides.
Quantification of the kinetic data of the interaction of
Vpr
75-90 with CypA was performed at low sample con-
centrations (10-80 nM) using a chip immobilized to 918
RU (Figure 1A and Table 1). The association and disso-
ciation curves fitted well to a 1:1 binding model (Figure
1A), which was used to calculate the kinetic constants.
The dissociation constant (KD) for the interaction was
determined to be approximately 0.28 μM (Table 1).
Determination of the C-terminal binding region of Vpr to
CypA
To determine the exact C-terminal binding region of Vpr
to CypA, the potential interaction of the partly overlap-
ping C-terminal decapeptides Vpr
69-78,V p r
75-84,V p r
81-90
and Vpr
87-96 with CypA were analyzed by SPR spectro-
scopy. The sensorgrams revealed that these peptides
interacted only weakly with CypA (Figure 2). Hence the
complete C-terminal peptide Vpr
75-90, comprising the 16
Figure 1 Characterization of the specific interaction of C-terminal Vpr
75-90 with CypA and comparison with the interaction with N-
terminal binding domain of Vpr. (A) SPR sensorgrams for the specific interaction of synthetic Vpr
75-90 with CypA. The peptide was injected at
concentrations 0-80 nM over CM5 chip immobilized with CypA to 918 RU. The SPR sensorgrams were fitted to a 1:1 (Langmuir) binding model
(black line). (B-C) Comparison of interaction of Vpr
75-90 (B) and Vpr
30-40 (C) with CypA. The peptides were injected at concentrations ranging from
0-8 μM over CM5 chip immobilized to 180 RU with CypA. (B-C) illustrates the lower affinity of the previously characterized N-terminal binding
domain of Vpr [14] to CypA compared with the novel detected C-terminal binding domain.
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75GCRHSRIGVTRQRRAR
90,w a sr e q u i r e df o r
maintaining the strong interaction with CypA.
Mutation of Arg-80 with Ala significantly reduces the
binding affinity
Previous studies show that the C-terminal region is
important for most of the identified functions of Vpr,
and attention has especially been directed to the argi-
nine residues in the C-terminal region. As Arg-80 has
previously been reported to be necessary for maintaining
binding between Vpr and CypA [12], SPR experiments
were performed on the mutant peptides Vpr
75-90 R80A,
Vpr
75-90 (R76Q, V83I, T84I) and Vpr
75-90 (R76Q, V83I,
R80A, T84I). A reduction in association was observed
for all mutants compared with the wild-type (wt) peptide
(Table 1). Interestingly, the peptides with mutation of
Arg-80 (Vpr
75-90 R80A and Vpr
75-90 (R76Q, V83I, R80A,
T84I)) showed the lowest binding response (Figure 2).
The dissociation constant (KD) of the three mutants
were of the same order of magnitude (10
-6M) (Table 1).
The highest dissociation constant was found for Vpr
75-90
R80A, indicating that this mutant exhibits the weakest
binding to CypA. In summary, this implies an important
function of Arg-80 in maintaining a strong interaction
of the C-terminal binding region of Vpr to CypA, not-
withstanding the fact that other residues appear to influ-
ence the interaction between Vpr and CypA to some
extent. The fact that the decapeptide Vpr
75-84 fails to
bind to CypA (Figure 2) clearly demonstrates that Arg-
80 and its nearby surrounding residues are insufficient
for the interaction to occur. Reduced binding affinity
was also observed for the mutant peptide Vpr
75-90
(R76Q, V83I, T84I) where Arg-80 was conserved (Figure
2), demonstrating the importance of an intact 16 residue
C-terminal binding domain of Vpr.
Mutation of Arg-80 with Ala does not influence the weak
secondary structure of the C-terminal binding domain of
Vpr
Previous NMR studies on Vpr [45] showed that the C-
terminal binding domain of Vpr to CypA is a region
that only exhibits weak secondary structure. To reveal
whether or not the R80A mutation influences the sec-
ondary structure of the binding domain, NMR spectra
of wt Vpr
75-90 and Vpr
75-90 R80A dissolved in aqueous
solution in the presence of 100 mM dodecylphospho-
choline (DPC) were recorded and chemical shift index
(CSI) were performed. CSI are plots of the chemical
shift differences of the a-protons relative to that of
residues in a random coil and is commonly accepted
to identify regions with secondary structure in peptides
and proteins [46]. It has been shown experimentally
that a-proton chemical shifts greater than 0.1 ppm
relative to the random coil values are qualitative indi-
cators of protein secondary structure [46]. A minimum
of four adjacent residues with an upfield shift are indi-
cative of an a-helix, whereas b-sheets require a mini-
mum of three residues with downfield shifts [46]. CSI
showed that the weak secondary structure of the bind-
ing region of Vpr is consistent with that previously
reported by others in the literature [45] and is rela-
tively uninfluenced by the R80A mutation (Figure 3).
Table 1 Estimated kinetic constants for binding of full-length HIV-1 Vpr and C-terminal Vpr peptides to CypA.
Peptide Amino acid sequence Model Kinetic constants
KD(μM) ka1(1/Ms) kd(1/s)
Vpr
75-90 GCRHSRIGVTRQRRAR 1:1 0.28 ± 0.27 8.1 ± 6.1 × 10
4 6.3 ± 4.6 × 10
-3
Vpr
75-90 (R76Q, V83I, T84I) GCQHSRIGIIRQRRAR 1:1 4.7 ± 2.6 1.6 ± 0.1 × 10
4 0.071 ± 0.037
Vpr
75-90 (R76Q, V83I, R80A, T84I) GCQHSAIGIIRQRRAR 1:1 2.7 ± 1.9 4.2 ± 0.8 × 10
4 0.095 ± 0.061
Vpr
75-90 (R80A) GCRHSAIGVTRQRRAR 1:1 7.5 ± 2.6 3.8 ± 0.6 × 10
3 0.027 ± 0.005
Vpr
69-78 FIHFRIGCRH *
Vpr
75-84 GCRHSRIGVT *
Vpr
81-90 IGVTRQRRAR *
Vpr
87-96 RRARNGASRS *
Vpr
1-96 (918 RU CypA) BA ka1 = 1.3 ± 1.0 × 10
4
ka2 = 5.9 ± 1.7 × 10
-6
kd1 = 1.8 ± 0.2 × 10
-3
kd2 = 6.7 ± 3.8 × 10
-4
Vpr
1-96 (918 RU CypA) 1:1 0.31 ± 0.28 3.2 ± 1.2 × 10
4 0.007 ± 0.005
Vpr
1-96 (180 RU CypA) BA ka1 = 5.8 ± 0.8 × 10
3
ka2 = 1.6 ± 1.6 × 10
-4
kd1 = 0.022 ± 0.025
kd2 = 7.3 ± 4.0 × 10
-4
Vpr
1-96 (180 RU CypA) 1:1 0.32 ± 0.14 1.6 ± 0.6 × 10
4 4.22 ± 0.4 × 10
-3
The data represent mean values ± S.E. of two individual experiments using four different concentrations containing duplicate of one concentration.
*KD not measurable by the Biacore instrument.
1:1, Langmuir binding
BA, Bivalent analyte
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Page 4 of 16Figure 2 Characterization of C-terminal Vpr peptides interacting with CypA. SPR sensorgrams for synthetic Vpr
75-90, the mutants Vpr
75-90
(R76Q, V83I, T84I), Vpr
75-90 (R76Q, V83I, R80A, T84I), Vpr
75-90 (R80A) and the shorter peptides Vpr
69-78, Vpr
75-84, Vpr
81-90 and Vpr
87-96 were analyzed
for binding to immobilized recombinant CypA. The peptides were injected at concentrations ranging from 0-8 μM over CM5 chip immobilized
to 150 RU with CypA.
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Page 5 of 16Figure 3 Mutation of Arg-80 with Ala does not influence the secondary structure of Vpr
75-90. Chemical shift differences (ppm) of the a-
protons between the experimental values and those for residues in a random coil for Vpr
75-90 (A) and sVpr
75-90 R80A (B) in H2O-D2O 9:1 (v/v)
containing 100 mM DPC-d38 at 300 K.
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Page 6 of 16C-terminal Vpr binding to CypA confirmed by Isothermal
titration calorimetry
To independently confirm the binding of C-terminal
Vpr
75-90 to CypA, and to verify the binding constant
measured by SPR spectroscopy, isothermal titration
calorimetry (ITC) titration was performed. The ITC
analysis confirmed the high affinity interaction between
Vpr
75-90 and CypA (Figure 4), and the mean dissociation
constant from two independent titrations was found to
be 0.09 μM (Table 2). The ITC experiment thereby veri-
fies the approximate magnitude of the affinity of binding
found by SPR spectroscopy (KD 0.28 μM, Table 1).
Full length Vpr binds strongly to CypA as a bivalent
analyte
The N- and C-terminal binding regions of Vpr to CypA
were accurately determined by SPR biosensor analysis of
the interaction of N- and C-terminal peptides with a
varying number of residues. These data encouraged
characterization of the interaction of full-length Vpr
with CypA using SPR spectroscopy.
The SPR analysis of the interaction of full-length Vpr
with CypA were performed with different analyte con-
centrations ranging from 10 nM to 8 μM and different
ligand densities of CypA (150 RU, 180RU, 918 RU and
5003 RU). Comparison of the sensorgrams detected for
Vpr
1-96 injected at concentrations ranging from 10-80
nM over a CM5 chip immobilized with 180 RU (Figure
5A), and over an analogous chip immobilized with 918
RU CypA (Figure 5B), shows a significant increase in
response with increased CypA concentration immobi-
lized on the chip. Thus, interaction analysis using lower
concentrations of Vpr becomes accessible with applica-
tion of higher chip densities of CypA. For full-length
Vpr, concentrations ranging from 100 to 800 nM and a
chip density of 180 RU CypA proved to be the optimum
experimental condition for quantification of the interac-
tion. Moreover, the sensorgrams obtained for the inter-
action of Vpr
1-96 with immobilized CypA revealed that
the full-length protein binds strongly to CypA (Figure
6). As can be seen from the sensorgrams, the strength
of the interaction seems primarily to be due to the slow
dissociation phase (Figure 6). To quantify the interac-
tion, the most appropriate binding model had to be
determined. Two binding sites have been identified in
Vpr, one N- and one C-terminal binding domain, which
independently have been determined to bind to CypA
by SPR spectroscopy. Consequently, the nature of the
interaction between full-length Vpr and CypA is
expected to be more complex than a 1:1 binding inter-
action. The presence of two binding sites of Vpr sug-
gests that Vpr may act as a bivalent analyte for CypA.
The question was whether these binding sites of Vpr
bind at the same site at CypA or to two different sites,
thus making CypA a heterogeneous ligand. Demange et
al. suggested that there are two different and function-
ally independent subsites at CypA, namely a S1’ proline
substrate dependent subsite delineated by Met-61, Ala-
101, Phe-113 and Leu-122 and a S2’-S3’ Phe-pNA sub-
site surrounded by Ile-57, Phe-60, Trp-121 and Arg-148
that are able to bind to peptides that do not contain Pro
residues [39].
As a consequence of our discovery that Vpr has one
proline containing N-terminal CypA binding region and
one non-proline containing C-terminal CypA binding
region, these most likely bind to the S1’ and S2’-S3’
binding sites of CypA, respectively. Hence, CypA could
be associated with both binding regions of Vpr simulta-
neously. Ardon et al. reported that both mutants Vpr
P35N and Vpr R80A failed to coprecipitate with CypA
[12], which implies that simultaneous binding of CypA
to both binding sites of Vpr is required for CypA to
bind to full length Vpr.
The SPR sensorgrams of the interaction of full-length
Vpr with immobilized CypA gave an excellent fit to the
bivalent analyte model. This strongly supports simulta-
neous binding of CypA with the N-terminal Pro-con-
taining binding region and the C-terminal non-Pro
binding region of Vpr, involving the S1’ (Pro-dependent)
and S2’-S3’ (Pro-independent) binding sites of CypA,
respectively (Figure 6). The stoichiometry of the interac-
tion is 1:1 and as an estimate, the interaction was quan-
tified from the simple 1:1 binding model. The
sensorgrams of Vpr
1-96 were fitted to a 1:1 binding
model by the Biacore evaluation software, and kinetic
constants were determined (Figure 6, Table 1). The dis-
sociation constant (KD) was determined to be approxi-
mately 320 nM.
Discussion
Recently we determined that the N-terminal binding
region of Vpr to CypA is comprised of the heptapeptide
32RHFPRIW
38 centered at Pro-35 [14]. Mutation of the
central Pro residue (P35A) causes a loss of binding
through disruption of the Pro-dependent N-terminal
heptapeptide binding region. In the context of the full
length molecule this mutation also results in merging of
helix 1 and 2, which in turn causes a substantial change
in the hydrophobic core of the protein as the anti-paral-
lel folded structure of the N-terminal and central helices
is no longer possible [38].
In this paper we have characterized a C-terminal
region of Vpr, comprising the 16 residues
75GCRHSRIGVTRQRRAR
90, with high binding affinity
for CypA. This region of Vpr does not contain any Pro
residues, but binds much more strongly to CypA than
to the N-terminal binding region (Figure 1). The fact
that the mutant peptide Vpr
75-90 R80A binds
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Page 7 of 16considerably weaker to CypA than the wt peptide (Fig-
ure 2) confirmed that Arg-80 is a key residue in the C-
terminal binding region. Arg-80 is considered to be
located in proximity to, but not included in, the well-
defined helix 3 (residues 55-77) of the structured pro-
tein formed under membranous conditions at physiolo-
gical pH [45]. The secondary structure NOEs of
r e s i d u e s7 8 - 9 0o ff u l l - l e n g t hV p rf o u n db yM o r e l l e te t
Figure 4 ITC analysis of Vpr
75-90 binding to CypA. Upper panel shows thermogram for the binding of Vpr
75-90 to CypA. Lower panel shows
the corresponding binding isotherms where each point represents the integrated heat of the associated peak in the thermogram.
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i+1), in addition to a few Ha-NH(i, i+2) and Ha-NH(i, i+3),
indicating that these residues comprise a region with a
relatively weak a-helical structure. Indeed, our NMR
data of wt Vpr
75-90 and Vpr
75-90 R80A confirmed this
interpretation and revealed that the propensity for weak
helical structure of the C-terminal binding region is
essentially unaffected by the mutation of Arg-80 to Ala
(Figure 3). Thus, the mutation prevents binding of Vpr
to CypA through a local change in the C-terminal bind-
ing region rather than any change in the tertiary struc-
ture of Vpr.
In aqueous solution Vpr is present as high order
aggregates (~decamers) with a lower percentage of
higher multimers [8]. According to Fritz et al. oligomer-
ization is mediated by the Vpr hydrophobic core but
not by the flexible N- and C-terminal domains [47]. The
C-terminal binding domain of Vpr to CypA is located
beyond the residues that have been shown experimen-
tally to be involved in oligomerization of Vpr. In agree-
ment with this we used the statistical mechanics
algorithm TANGO, which identifies aggregation-prone
regions of peptides and denatured proteins using a set
of balanced physico-chemical parameters [48,49].
According to the TANGO algorithm, a score of ≤ 0.02%
indicates no aggregation, 0.02-5.0% indicates moderate
aggregation, and ≥ 5.0% indicates high aggregation pro-
pensities. Application of this program predicted a region
of 16 residues (Ala-55 to Ile-70) populating the oligo-
merization state to more than 5% per residue (5.09 -
35.56% per residue). Four further residues were pre-
dicted with much lower score, namely Thr-53 (1.30%),
Trp-54 (3.50%), His-71 (0.84%) and Phe-72 (0.80%). The
fact that the dissociation constant of full-length Vpr is
in the same order of magnitude as the dissociation con-
stant of the C-terminal binding domain Vpr
75-90 does
not indicate that oligomerization of Vpr influences the
interaction with CypA significantly.
Previous studies have shown that the mutants Vpr
P35A and Vpr R80A were key residues for coimmuno-
precipitation of Vpr and CypA, and when replaced abro-
gated the coimmunoprecipitation to CypA [12].
Although, these authors concluded that residues beyond
Vpr
1-40 also are important for binding to CypA, no
further explanation was provided. Our data indepen-
dently confirm the importance of these residues for the
interactions and indicate that the C-terminal binding is
quantitatively stronger than the N-terminal binding to
CypA (Figure 1). However, the fact that the decapeptide
Vpr
75-84 fails to bind to CypA (Figure 2) clearly demon-
strates that Arg-80 and its nearby surrounding residues
are insufficient for the interaction to occur. Reduced
Table 2 Estimated kinetic constants for binding of HIV-1 Vpr
75-90 to CypA by ITC
Titration n Ka(×10
7 M
-1)K D(μM) ΔH(kcal/mol) -TΔS(kcal/mol)
1 0.98 0.9 0.12 -17.4 7.0
2 1.00 1.7 0.06 -16.5 7.5
Mean values ± S.E 1.3 ± 0.4 0.09 ± 0.03 -16.9 ± 0.5 7.3 ± 0.3
Figure 5 Characterization of binding of full-length Vpr to CypA. Characterization of CypA binding to full-lengthVpr at different chip
concentrations of CypA. The interaction of Vpr
1-96 with immobilized recombinant CypA was analyzed using SPR biosensor system. Vpr
1-96 was
injected over CM5 chips immobilized with different surface densities of CypA. Comparison of binding response curves detected for Vpr
1-96
injected at concentrations ranging from 0-80 nM over CM5 chip immobilized with 180 RU (A) and over chip immobilized with 918 RU CypA (B)
shows an increase in response with increased CypA concentration immobilized.
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Page 9 of 16Figure 6 Analysis of binding model for the full-length Vpr-CypA interaction. SPR sensorgrams of the interaction of synthetic Vpr
1-96 with
immobilized CypA. Vpr
1-96 was injected at concentrations 0-800 nM over CM5 chip immobilized with 180 RU CypA. The sensorgram was fitted
to a 1:1 interaction model (A), heterogenous ligand kinetic model (B) and to a bivalent analyte kinetic model (C) using the biacore evolution
program.
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Page 10 of 16binding affinity was also observed for a mutant Vpr
75-90
peptide where Arg-80 was conserved, demonstrating the
importance of an intact 16 residue C-terminal binding
domain of Vpr.
A simultaneous interaction of both Vpr sites with
CypA was suggested as SPR sensorgrams of full-length
Vpr interacting with immobilized CypA gave an optimal
fit with a bivalent analyte model (Figure 5). Taken
together, these data indicate that a simultaneous binding
of the N- and C-terminal domains is required for full-
length Vpr to interact with CypA. The dissociation con-
stant (KD) of full-length Vpr was found to be approxi-
mately 0.32 μM (Table 1), which implies that the Vpr-
CypA interaction may be stronger than the well charac-
terized interaction of HIV-1 CA with CypA, which has
been determined previously by SPR spectroscopy (KD 16
±4μM) [50]. This suggests that the CypA-Vpr interac-
tion has a functional role in the relationship between
the host and pathogen.
The access to detailed information of the interaction
of full-length Vpr with CypA, based on the experimental
characterization of the N- and C-terminal binding
domains of Vpr, now allows us to visualize the interac-
tion of full-length Vpr with CypA. As prerequisites, we
have used the NMR structure of Vpr [45] and X-ray
structure of CypA [51] as rigid units, together with
knowledge of the key residues of the Pro-dependent and
Pro-independent binding domains of CypA [39]. A car-
toon illustrating the Vpr-CypA complex based on these
parameters was generated with the ZDOCK algorithm
[52] and is shown in Figure 7. This crude model sug-
gests that a folded Vpr structure is required to provide
N- and C-terminal binding regions sufficiently close in
space in the Vpr-CypA complex (Figure 7) for the coop-
erative interaction with the two binding sites of CypA.
Currently one should keep in mind that the model has
its limitations but clearly rationalizes the findings pre-
sented here. The structure of Vpr used, which is the
potentially variable/flexible component of the model, is
the limiting structure at low pH in 30% aqueous aceto-
nitrile [45]. However, a more flexible structure of Vpr,
which would be expected under the hydrophilic condi-
tions at physiological pH [8,53] used in the Biacore
experiments performed to characterize the interaction,
would be beneficial for improving the model and, thus,
provide more accurate details of the interactions of the
Vpr-CypA complex at the atomic level.
Most residues of the N- and C-terminal binding
domains of Vpr are highly conserved among HIV-1
strains (with the exception of Ile-37 of the N-terminal
binding domain and Arg-77, Val-83, Thr-84, Arg-85,
Gln-86 and Ala-89 of the C-terminal binding [54]), indi-
cating that maintenance of these structural regions of
the protein is important for the viral life cycle.
The N-terminal Vpr binding domain is located
between helix 1 and 2, and the C-terminal Vpr binding
domain is located in an arginine-rich region in proxi-
mity to the third a-helical domain of Vpr (Figure 7).
Although the biological importance of the binding of
Vpr to CypA remains elusive, multiple functions of Vpr
are connected to the two regions of the protein which
bind cooperatively to CypA, including apoptosis [55-63],
reverse transcriptase (RT) activity [36,64-66], replication
of R5 tropic HIV-1 [38,67], nuclear localization of the
protein [30,31,68-70], G2 cell cycle arrest [30-36,71] and
binding of Vpr to DNA and RNA, which is linked to the
ability of activating the ATR (ataxia-telangiectasia and
Rad3-related) pathway leading to G2 arrest [72-75] (Fig-
ure 8). The importance of both domains to achieve
binding of full-length Vpr to CypA suggests that the
biological relevance of the interaction may be associated
with other functional interactions of Vpr involving both
the N- and C-terminal regions (Figure 8). Previous stu-
dies have presented contradictory results regarding the
possibility that the interaction of Vpr with CypA is
involved in induction of G2 arrest or that it has any
effect on Vpr expression [12,13]. However, other studies
have independently shown that Vpr induced G2 arrest is
dependent on residues belonging to both the N- and C-
terminal binding regions of Vpr to CypA [30-36,71].
Residues within the C-terminal domain of Vpr including
Arg-80, which was found essential for retaining a strong
binding to CypA in this study, are also considered to be
important for increasing RT activity [36] and Vpr
induced apoptosis [56,60,61]. Furthermore, residues in
the N-terminal binding region of Vpr are important for
Vpr induced apoptosis (Figure 8) [57,58,62], indicating
that, both the N- and C-terminal CypA binding domains
are involved in this function of Vpr. Moreover, the
nuclear localization of Vpr and replication of R5 tropic
HIV-1 are related to residues included in both N- and
C-terminal CypA binding domains of Vpr (Figure 8).
The identification of N- and C-terminal binding
domains of Vpr, which cooperatively bind to CypA (Fig-
ure 7), should encourage further investigations into the
biological relevance of the interaction of Vpr with the
host cellular factor CypA, as it is likely that this strong
interaction is of importance in the viral life cycle of
HIV-1.
Conclusions
CypA may represent a potential key molecule in future
antiretroviral therapy since inhibition of CypA sup-
presses HIV-1 replication. All previous studies of pro-
tein-protein interactions involving human CypA have
hitherto been limited to Pro-containing substrates. The
fact that a non-proline-containing 16-residue region of a
protein is able to bind with high affinity to CypA,
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Page 11 of 16Figure 7 Cartoon of the complex of Vpr and CypA. The cartoon shows the 30 KDa complex of CypA with full-length Vpr where selected
residues of the cooperative N- and C-terminal binding domains of Vpr and the two binding sites of CypA suggested by Demange et al. are
high-lighted [30]. Residues Pro-35 and Arg-80 of Vpr are highlighted in yellow. Leu-122 of the Pro-dependent S1’ subsite and Arg-148 of the Pro-
independent S2’-S3’ subsite of CypA are highlighted in green [30]. The structures of CypA and Vpr used in the model of the complex are
derived from the pdb files of the X-ray structure of CypA at 1.63 Å resolution [51] and the NMR structure of Vpr obtained in aqueous 30%
acetonitrile solution at low pH [45]. At physiological pH Vpr is mainly structured in a membranous environment and exhibits a more flexible
structure under hydrophilic solution which is similar to the experimental conditions used in the SPR experiments (aqueous buffer pH 7.4) [8,53].
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Page 12 of 16presented for the first time in this manuscript, changes
the view on how CypA is able to interact with other
proteins. It is interesting to note that several previously
reported key functions of HIV-1 are associated with the
identified N- and C-terminal binding domains of the
protein to CypA.
Methods
Peptide synthesis
The synthesis, purification and molecular characteri-
zation of synthetic Vpr
1-96 (sVpr), the C-terminal pep-
tides Vpr
75-90 ,V p r
69-78,V p r
75-84,V p r
81-90 and Vpr
87-
96 and the mutants Vpr
75-90 (R76Q, V83I, T84I),
Vpr
75-90 (R76Q, V83I, R80A, T84I), Vpr
75-90 (R80A)
were performed as described in detail elsewhere [8,53]
and the purities were checked by HPLC, MALDI-MS
and positive ion ESI-MS [14]. The mass spectrum of
sVpr exhibited a significant M-18 peak corresponding
to loss of a water molecule from the intact protein
during synthesis. As tandem mass spectrometry (MS/
MS) analysis revealed that the water molecule was
eliminated from residues 6 or 7, belonging to a region
that has been experimentally shown not to bind to
CypA [14], the protein was considered suitable for
our studies.
Cyclophilin A (CypA)
The production and purification of recombinant human
CypA has been described previously [14].
Nuclear magnetic resonance spectroscopy
2D
1H Total correlation spectroscopy (TOCSY) and
nuclear Overhauser enhancement spectroscopy
(NOESY) NMR experiments were performed at 600.13
MHz on a Bruker Avance 600 MHz instrument
equipped with an UltraShield Plus magnet and a triple
resonance cryoprobe with gradient unit. Individual sam-
ples were dissolved in 600 μl1 0 0m Ma q u e o u sD P C -
d38 micelles 10% D2O (v/v) at concentrations between
1-2 mM. The 2D NMR experiments were performed at
300 K without spinning with mixing times of 110 ms for
the TOCSY experiments and 250 ms for the NOESY
experiments. Efficient suppression of the water signal
was achieved by application of excitation sculpting in
the 1D
1Ha n dt h e2 D
1HT O C S Ya n dN O E S YN M R
experiments [76].
1H signal assignments of the NMR
spectra were achieved by identification of the individual
spin systems in the 2D
1H TOCSY spectra, combined
with observations of sequence-specific short-distance
crosspeaks (Ha-HN i, i+1) in the 2D
1H-
1HN O E S Y
spectra [53,77]. Readily recognizable spin systems were
Figure 8 Previously determined biological functions associated with the N- and C-terminal binding domains of Vpr to CypA.L i n e a r
structure of full length Vpr with incorporated biological functions connected to the determined N- and C-terminal binding regions of Vpr to
CypA including G2 cell cycle arrest [30-34,36,71], nuclear localization of the protein [30,31,68-70], ANT/apoptosis [55-63], and replication of R5
tropic HIV-1 [38,67]. Residues belonging to the N- and C-terminal binding regions of Vpr to CypA are labeled in blue.
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Page 13 of 16used as starting points for correlation of the individual
spin systems observed in the TOCSY and NOESY spec-
tra with individual residues in the peptide sequences.
Acquisition of data, processing and spectral analysis
were performed with Bruker Topspin 1.3 software.
Surface plasmon resonance spectroscopy
SPR [42-44] measurements were performed at 25°C on a
Biacore T100 instrument (Biacore AB, Uppsala, Sweden)
equipped with CM5 research-grade sensor chips. CypA
was immobilized to 150, 180, 918 and 5003 RU, using
standard amine-coupling chemistry. The reference flow
cells were treated correspondingly except for CypA
immobilization. The synthetic full length Vpr, as well as
fragments and mutants thereof, were dissolved at four
different concentrations in the running buffer (HBS-EP
buffer pH 7.4; 10 mM HEPES, 150 mM NaCl, 3.4 mM
EDTA and 0.005% surfacant). The samples were injected
over the flow cells at a flow rate of 30 μl/min. Data were
collected at 2.5 Hz during 60 s association and 180 s or
240 s dissociation phases, and were automatically cor-
rected for bulk buffer effects and non-specific binding of
Vpr peptides to the chip matrix. All SPR data was
acquired from two individual series of experiments
using four different analyte concentrations with a dupli-
cate injection of one of the individual concentrations.
Analysis of biosensor data
Affinity, association and dissociation rate constants were
obtained from sensorgrams by the Biacore T100 evalua-
tion software version 2.0.1 in accordance with the global
curve fit model. Sensorgram data for the four different
concentrations were fitted to several binding models
including 1:1 (Langmuir) binding model (A+B ↔ AB),
two-state reaction (conformational change) model (A+B
↔ AB ↔ AB*), heterogeneous ligand (HL) model (inter-
action one: A+B1 ↔ AB1; interaction two: A+B2 ↔
AB2) and bivalent analyte (BA) model (A+B ↔ AB; AB
+B↔ABB). Kinetic constants were calculated for the
best fitted model.
Isothermal titration calorimetry
ITC was performed in a VP-ITC titration calorimeter
(MicroCal Inc.). CypA and Vpr
75-90 were prepared in fil-
t e r e dH B S - E Pb u f f e rp H7 . 4a n dt h es a m p l e sw e r e
degassed prior to titration. Two individual titrations
were performed by adding 14.8 μMa n d1 1μMC y p A ,
respectively to the sample cell and titrated with a 210
μM stock solution of Vpr
75-90. CypA samples were sub-
jected to 30-50 injections (5-10 μL) of the Vpr
75-90 pep-
tide with a 360 or 420 s interval between each injection
at 25°C. The mean of the heat from the last 5 injections
was subtracted from the raw data to correct for experi-
mental heat dilution. The binding isotherms were fitted
to a one site binding model using the Origin v7 software
(OriginLab). Chi-square minimization was performed
iteratively to obtain the best-fit parameters.
Docking analysis of the Vpr-CypA complex
A cartoon of the Vpr-CypA complex was generated
based on the detailed experimental characterization of
the N- and C-terminal binding domains of Vpr using
the ZDOCK algorithm [52]. The X-ray structure of
CypA (pdb entry 3K0N) [51] and the NMR structure of
Vpr (pdb entry 1M8L) [45] were used as rigid units,
together with knowledge of the key residues of the Pro-
dependent and Pro-independent binding domains of
CypA.
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